Abstract: Disclosed are compositions comprising an engineered intein designed such that the self-cleaving activity of the intein can be modulated by a zinc-binding motif as well as methods and systems for making and using the compositions.

Abstract: Disclosed are compositions comprising an engineered intein designed such that the self-cleaving activity of the intein can be modulated by a zinc-binding motif as well as methods and systems for making and using the compositions.

Abstract: Disclosed are compositions comprising an engineered intein designed such that the self-cleaving activity of the intein can be modulated by a zinc-binding motif as well as methods and systems for making and using the compositions.

Abstract: Disclosed are compositions comprising an engineered intein designed such that the self-cleaving activity of the intein can be modulated by a zinc-binding motif as well as DNA methods and systems for making and using the compositions.

Abstract: The invention provides IL-15 amino acid sequences with amino acid substitutions that reduce or eliminate deamidation of IL-15 and degradation by-products. The invention also provides DNA sequences that encode the substituted amino acid sequences, a pharmaceutical composition comprising the substituted IL-15 amino acid sequence and a pharmaceutically acceptable carrier, and a method of treating a condition in a mammalian host comprising administering to the host the substituted IL-15 amino acid sequence or the pharmaceutical composition including the substituted IL-15 amino acid sequence in an amount effective to treat the condition in the host.

Abstract: The invention provides IL-15 amino acid sequences with amino acid substitutions that reduce or eliminate deamidation of IL-15 and degradation by-products. The invention also provides DNA sequences that encode the substituted amino acid sequences, a pharmaceutical composition comprising the substituted IL-15 amino acid sequence and a pharmaceutically acceptable carrier, and a method of treating a condition in a mammalian host comprising administering to the host the substituted IL-15 amino acid sequence or the pharmaceutical composition including the substituted IL-15 amino acid sequence in an amount effective to treat the condition in the host.

Abstract: This disclosure concerns compositions and methods for the treatment and inhibition of infectious disease, particularly bubonic and pneumonic plague. In certain embodiments, the disclosure concerns immunogenic proteins, for instance substantially monodisperse F1-V fusion proteins, that are useful for inducing protective immunity against Y. pestis.

Abstract: A system, method and computer program product is provided for processing images of an electrophoretic separation medium to determine the unit activity of an enzyme. A test aliquot, comprising a macromolecule (such as, DNA, RNA, protein, peptide or the like) and diluted enzyme concentration, is distributed in the separation medium. The enzyme concentration acts as a catalysis to cleave the macromolecule into distinct fragments during electrophoresis. A set of intensity data profiles are produced from images of the fragments. The profiles are stacked and vertically aligned to designate and assign the fragments to their respective lanes. A group of partial bands and final bands are selected from the fragments. Peak integrations are implemented to measure the intensity of the partial and final bands. A series of intensity ratios are computed from the peak integrations. The intensity ratios are normalized and plotted to produce a trend.

Abstract: A system, method and computer program product is provided for processing images of an electrophoretic separation medium to determine the unit activity of an enzyme. A test aliquot, comprising a macromolecule (such as, DNA, RNA, protein, peptide or the like) and diluted enzyme concentration, is distributed in the separation medium. The enzyme concentration acts as a catalysis to cleave the macromolecule into distinct fragments during electrophoresis. A set of intensity data profiles are produced from images of the fragments. The profiles are stacked and vertically aligned to designate and assign the fragments to their respective lanes. A group of partial bands and final bands are selected from the fragments. Peak integrations are implemented to measure the intensity of the partial and final bands. A series of intensity ratios are computed from the peak integrations. The intensity ratios are normalized and plotted to produce a trend.

Abstract: A system, method and computer program product is provided for processing images of an electrophoretic separation medium to determine the unit activity of an enzyme. A test aliquot, comprising a macromolecule (such as, DNA, RNA, protein, peptide or the like) and diluted enzyme concentration, is distributed in the separation medium. The enzyme concentration acts as a catalysis to cleave the macromolecule into distinct fragments during electrophoresis. A set of intensity data profiles are produced from images of the fragments. The profiles are stacked and vertically aligned to designate and assign the fragments to their respective lanes. A group of partial bands and final bands are selected from the fragments. Peak integrations are implemented to measure the intensity of the partial and final bands. A series of intensity ratios are computed from the peak integrations. The intensity ratios are normalized and plotted to produce a trend.